These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22621693)

  • 1. Treatment of pulmonary arterial hypertension in connective tissue disease.
    Grünig E
    Drugs; 2012 May; 72(8):1039-56. PubMed ID: 22621693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Kuang HY; Li Q; Du HA; Chen M; Yin YH
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
    Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled treprostinil: a therapeutic review.
    Channick RN; Voswinckel R; Rubin LJ
    Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
    Erdogan M; Esatoglu SN; Kilickiran Avci B; Hatemi G
    Intern Emerg Med; 2024 Apr; 19(3):731-743. PubMed ID: 38378970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic Differences in Connective Tissue Disease-Associated Versus Idiopathic Pulmonary Arterial Hypertension in the PVDOMICS Cohort.
    Simpson CE; Hemnes AR; Griffiths M; Grunig G; Tang WHW; Garcia JGN; Barnard J; Comhair SA; Damico RL; Mathai SC; Hassoun PM;
    Arthritis Rheumatol; 2023 Dec; 75(12):2240-2251. PubMed ID: 37335853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic Cell Subsets and Effector Function in Idiopathic and Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
    van Uden D; Boomars K; Kool M
    Front Immunol; 2019; 10():11. PubMed ID: 30723471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension.
    Ramjug S; Hussain N; Hurdman J; Elliot CA; Sabroe I; Armstrong IJ; Billings C; Hamilton N; Kiely DG; Condliffe R
    Respirology; 2017 Feb; 22(2):372-377. PubMed ID: 27651181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension.
    Kularatne M; Boucly A; Savale L; Solinas S; Cheron C; Roche A; Jevnikar M; Jaïs X; Montani D; Humbert M; Sitbon O
    Expert Opin Pharmacother; 2023; 24(18):2101-2115. PubMed ID: 37869785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
    Chung L; Liu J; Parsons L; Hassoun PM; McGoon M; Badesch DB; Miller DP; Nicolls MR; Zamanian RT
    Chest; 2010 Dec; 138(6):1383-94. PubMed ID: 20507945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
    Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
    Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
    Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M
    Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity.
    Favoino E; Prete M; Liakouli V; Leone P; Sisto A; Navarini L; Vomero M; Ciccia F; Ruscitti P; Racanelli V; Giacomelli R; Perosa F
    Autoimmun Rev; 2024 Apr; 23(4):103514. PubMed ID: 38181859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease.
    Nakanishi N; ;
    Allergol Int; 2011 Dec; 60(4):419-24. PubMed ID: 22015568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
    Distler O; Ofner C; Huscher D; Jordan S; Ulrich S; Stähler G; Grünig E; Held M; Ghofrani HA; Claussen M; Lange TJ; Klose H; Rosenkranz S; Vonk-Noordegraaf A; Vizza CD; Delcroix M; Opitz C; Pausch C; Scelsi L; Neurohr C; Olsson KM; Coghlan JG; Halank M; Skowasch D; Behr J; Milger K; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Wilkens H; Pittrow D; Hoeper MM; Ewert R
    Rheumatology (Oxford); 2024 Apr; 63(4):1139-1146. PubMed ID: 37462520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.
    Zhao J; Wang Q; Deng X; Qian J; Tian Z; Liu Y; Li M; Zeng X
    Pharmacol Ther; 2022 Nov; 239():108192. PubMed ID: 35461923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.